Regulators In Focus As Amgen Launches Innovative Biologics Plant In Singapore
This article was originally published in PharmAsia News
Executive Summary
Amgen has launched a state-of-the art biologics manufacturing plant in Singapore that required one-quarter of the capital investment of a conventional operation, operates one-third cheaper and took half the time to build, according to CEO and Chairman Bob Bradway, who added the company plans to build a second one at the same site. But clinical and GMP certifications mean a wait until 2016 before commercial output.